Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group

The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) in a note issued to investors on Monday, Marketbeat.com reports. The firm set a "buy" rating and a $37.00 price target on the stock. The Goldman Sachs Group's price target would suggest a potential upside of 71.53% from the company's current price.

Other analysts also recently issued research reports about the stock. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Jones Trading reduced their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $39.60.

Enliven Therapeutics Stock Down 1.1%

Enliven Therapeutics stock traded down $0.23 during mid-day trading on Monday, hitting $21.57. 423,893 shares of the stock were exchanged, compared to its average volume of 292,627. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $30.03. The firm's fifty day simple moving average is $18.65 and its two-hundred day simple moving average is $20.61. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.23 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total transaction of $69,322.50. Following the transaction, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at $490,590. The trade was a 12.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $18.04, for a total value of $120,272.68. Following the completion of the sale, the chief operating officer now owns 316,643 shares in the company, valued at $5,712,239.72. This represents a 2.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 88,611 shares of company stock valued at $1,695,914 in the last quarter. 25.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after acquiring an additional 1,114 shares during the period. GAMMA Investing LLC raised its stake in Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after acquiring an additional 2,630 shares during the period. Quantbot Technologies LP bought a new stake in Enliven Therapeutics in the 1st quarter valued at about $60,000. KLP Kapitalforvaltning AS bought a new stake in Enliven Therapeutics in the 4th quarter valued at about $97,000. Finally, BNP Paribas Financial Markets bought a new stake in Enliven Therapeutics in the 4th quarter valued at about $112,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.